AusperBio to Present Long-Term Follow-Up Data of AHB-137 Treatment in Chronic Hepatitis B in Two Late-Breaking Oral Presentations at AASLD The Liver Meeting® 2026

Barchart · 1d ago

SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together, "AusperBio"), a near-commercial biopharmaceutical company, today announced that two abstracts reporting long-term follow-up data of AHB-137 treatment have been selected for late-breaking oral presentations at The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), to be held November 5–9 in Denver, Colorado, USA.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.